PPARA and pulmonary fibrosis: Lanifibranor, the PPARα/δ/γ pan agonist developed by Inventiva (Daix, France) [31], was first described for its prevention of experimental skin [38] and lung fibrosis [39], and was then applied to liver fibrosis [40].